Cellino

🚀 Today marks an extraordinary milestone at Cellino! We are thrilled to announce that our team has been awarded up to $25M in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS). This funding will drive the development of our ultra-scalable, autonomous, cassette-based advanced biomanufacturing technology for personalized regenerative medicine. Cellino’s NEBULA (NExt-generation Biomanufacturing ULtra-scalable Approach) project is the first project funded by the Scalable Solutions Mission Office under the ARPA-H Open Broad Agency Announcement. With ARPA-H’s support, Cellino will build a cassette-based biomanufacturing technology capable of scaling the production of personalized induced pluripotent stem cells at hospitals nationwide to develop curative medicines for a range of chronic conditions for an increasingly diverse and aging U.S. patient population. We are excited to move closer to making “Your Cells, Your Cure™” a reality for millions of patients. We are thrilled about this opportunity to advance our goal of making patient-specific stem cell-derived therapies available for broad patient audiences. 📄 Read the full release: https://bwnews.pr/4gfrjlb #ARPAH #Biotech #AI #MachineLearning #PersonalizedMedicine #Collaboration #Innovation #RegenerativeMedicine #BiotechBreakthroughs #CellinoBio #YourCellsYourCure #Biomanufacturing

🌟 Explore the future of regenerative medicine at #BioFuture2024 this week! Join Nabiha Saklayen, Cellino CEO & Co-Founder, and Susan Hockfield, President Emerita of Massachusetts Institute of Technology, at 9 AM ET on Wednesday, October 30, for a Fireside Chat on "The Convergence of AI and Biomanufacturing: Pioneering the Future of Regenerative Medicine."  Moderator Kimberly Ha, Founder & CEO of KKH Advisors, will lead the discussion as they cover key topics including: 🔷 The shift from traditional therapeutics to personalized cellular therapies 🔷 How living medicines derived from a patient’s own cells can potentially cure chronic diseases 🔷 Challenges and opportunities in scaling regenerative medicine for widespread use 🔷 Recent advancements in biomanufacturing for cell therapies Register and find us on the BioFuture™ meeting platform from October 28-30 to connect at the event or request  a virtual one-to-one meeting: https://lnkd.in/gV-2q65m We can’t wait to connect and work together toward improving healthcare outcomes for all patients! 🚀 #DemyColton #Biotech #AI #MachineLearning #Innovation #RegenMed #Therapeutics #PersonalizedMedicine #FutureofHealthCare #YourCellsYourCure #CellinoBio

🚀 We’re excited for tomorrow’s Longwood Healthcare Leaders Boston CEO Forum! Marinna Madrid, PhD, our Co-Founder & Chief Product Officer, will be joining industry leaders to discuss the latest research and development of biomanufacturing technologies. She’ll be speaking on the panel "Biomanufacturing: Planning for Future Success," led by moderator Andrew Obenshain, CEO of bluebird bio, and will share Cellino’s scalable solutions to industrializing autologous cell-based therapies! Marinna will be joined by Al Gianchetti, CEO of XyloCor Therapeutics, Inc., and Hari Pujar, COO of Tessera Therapeutics. We can’t wait to see everyone there for another engaging conversation on advancing personalized regenerative medicines! 🙌 🗓️ Join us and register here:  https://bit.ly/4dT37mf #BostonCEO #Biomanufacturing #Leadership #RegenMed #Innovation #PersonalizedMedicine #FutureofMedicine #Therapeutics #Cellino #YourCellsYourCure

🚀 Less than a month to go until NextGen Biomed by Oxford Global’s Cell 2024 in #London! Featuring global leaders in the cell and gene therapy space, this conference offers a comprehensive outlook on advancements in every step of the CGT value chain. Our CEO & Co-Founder, Nabiha Saklayen, will be speaking at this premier gathering on November 7-8, 2024. Make sure to mark these sessions on your calendar: 🔹 November 7, 2024 from 10:00 AM - 11:00 AM GMT – Panel Discussion: Advancing Cell Therapies: Exploring Quality Control & Personalized Medicine Integration. 🎤 Nabiha will speak on a panel featuring Zhong Yu, Scientific Liaisons Manager at Axion BioSystems, Monica Raimo, Director of Product and Process Development at Glycostem Therapeutics, and Nicolas Weber, Quality Team Leader QC at Novartis, moderated by Philippe Henon, Founder & Chairman of the Board at CellProthera SAS. 🔹 November 8, 2024 from 1:30 PM - 2:00 PM GMT – iPSCs and Stem Cell Therapy Development (Track 4): AI-Driven Biomanufacturing of Cell and Tissue Replacements. 🎤 Nabiha will present on Cellino’s optical bioprocess, which combines optics and image-guided machine learning for iPSC management, as well as optical cassette-based manufacturing for scalable production of cells and tissues. Register and see the full agenda here: https://lnkd.in/gh3MaE7U #OxfordGlobal #NextGenBiomed #Biotech #AI #MachineLearning #Innovation #RegenMed #Therapeutics #PersonalizedMedicine #FutureofHealthCare #YourCellsYourCure #CellinoBio

🚀 Don’t Miss This Conversation! 🚀 Our Co-Founder & CEO Nabiha Saklayen sits down with our newest board member, Chris Gibson, Co-Founder and CEO of Recursion, to explore their journeys and the future of personalized regenerative medicine. In this candid conversation, they dive into: 🎯 Their journeys as founder-CEOs 🤝 Building multidisciplinary teams that thrive at the interface of technical fields 💡 Personal motivations driving their passion for creating transformative impact for patients 🤖 The role of AI in shaping the future of personalized regenerative medicine If you’re curious about leadership, team-building strategies, or the exciting intersection of AI and healthcare, you won’t want to miss this engaging discussion. 👉 Watch the full video here: https://lnkd.in/eUs7SEpa #Leadership #RegenerativeMedicine #AI #BiotechInnovation #FutureOfHealthcare #FoundersJourney #TeamBuilding #PersonalizedMedicine

🚨 **Exciting News!** 🚨 We are thrilled to announce that Chris Gibson, Ph.D., Co-Founder and CEO of Recursion, has joined the Cellino Board of Directors! 🎉 As an experienced founder-CEO, Chris brings deep expertise in scaling multi-disciplinary teams and pushing the boundaries of healthcare innovation using AI, along with a passion for developing novel therapies for patients with significant unmet medical need. As we continue on the exciting journey of making personalized regenerative therapies available to patients, we are humbled to have Chris’ invaluable expertise and leadership as part of our Board! 🚀🚀 Check out the full press release at: https://lnkd.in/eCtBUemy #BoardAnnouncement #Leadership #Biotech #Innovation #RegenerativeMedicine #FutureForward

🚀🌐 Our CEO & Co-Founder, Nabiha Saklayen, will be heading to #London to speak at the FT Live Global Pharma and Biotech Summit 2024 (#FTPharma) from November 5-7, 2024. Nabiha will join an esteemed panel with Helen Tayton-Martin, Chief Business and Strategy Officer at Adaptimmune, and Andrew Dunn, Senior Biopharma Correspondent at Endpoints News. Their session, “Bringing the World’s Most Innovative and Expensive Treatments to Its Least-Wealthy Places,” on November 6 from 2:35 PM GMT / 10:35 AM ET, will explore how personalized cell-based therapies have the potential to revolutionize healthcare worldwide. They’ll also discuss the innovations needed in manufacturing, regulation, and access to ensure these treatments reach underserved populations worldwide. The panel will address the following questions: 🔹 How are biopharma companies, policymakers, and payers working to support access to innovative treatments? 🔹 What will it take to bring therapies like cell and gene treatments to the billions who can’t afford them? 🔹 How will manufacturing capabilities and commercial models evolve by the end of this decade? 🔹 How can health systems in developing countries adapt to provide access to these advanced treatments?  👉 Register now and mark your calendar for this key session at the summit: https://lnkd.in/d_xAnfZc #FinancialTimes #Biotech #AI #MachineLearning #Innovation #RegenMed #Therapeutics #PersonalizedMedicine #FutureofHealthCare #YourCellsYourCure #CellinoBio

🎤 Cellino CEO & Co-Founder, Nabiha Saklayen, will be speaking at Demy-Colton’s #BioFuture2024 next week in #NYC! Join her and Susan Hockfield, President Emerita of Massachusetts Institute of Technology, for a Fireside Chat on "The Convergence of AI and Biomanufacturing: Pioneering the Future of Regenerative Medicine." Moderator Kimberly Ha, Founder & CEO of KKH Advisors, will lead the conversation as they discuss how #AI-driven breakthroughs in #biomanufacturing are transforming regenerative medicine. The discussion on Wednesday, October 30 will cover key topics such as: 🔷 The shift from traditional therapeutics to personalized cellular therapies 🔷 How living medicines derived from a patient’s own cells can potentially cure chronic diseases 🔷 Challenges and opportunities in scaling regenerative medicine for widespread use 🔷 Recent advancements in biomanufacturing for cell therapies Register and find us on the BioFuture™ meeting platform from October 28-30 to connect at the event or request a virtual one-to-one meeting: https://lnkd.in/gV-2q65m We’re excited to connect and discuss how we can collectively improve healthcare outcomes for all patients! 🚀 #DemyColton #Biotech #AI #MachineLearning #Innovation #RegenMed #Therapeutics #PersonalizedMedicine #FutureofHealthcare #YourCellsYourCure #CellinoBio

🚀 We’re excited to announce that a limited number of complimentary spots are now available to professionals & leaders in the field for this year’s Personalized RegenMed Forum on Nov. 14-15 in Cambridge, MA! 🎉 This is your chance to be part of an exclusive gathering of innovators driving the future of personalized regenerative medicine. With attendees from 5 countries and a robust agenda featuring leading voices such as: 🔹Vinod Khosla, Founder and Partner, Khosla Ventures 🔹Sue Siegel, Board Member of Align, Nevro, Illumina, KFF, and Chairman of the Board of The Engine Accelerator 🔹Kapil Bharti, Scientific Director, National Eye Institute (NEI) Intramural Research Program, National Institutes of Health …and many more influential leaders shaping the future of healthcare. This year, we’re also exploring the power of AI in advancing regenerative medicine – a key theme throughout the event, offering a unique glimpse into how cutting-edge technology is transforming the future of care. This year’s theme, “Catalyze” marks how we are gathering to accelerate innovation for patients. Spots are limited, and they won’t last long! ⏳Secure your seat today and be part of conversations that will shape the future of personalized regenerative medicine. 👉View the program: https://lnkd.in/ecwSwbPK  👉 Register now: https://lnkd.in/eSpppxV4 For more information, please check out prmforum.com! 🚀 #RegenMedForum #PersonalizedMedicine #Innovation #Healthcare #RegenerativeMedicine #AI #FutureOfHealth

We’re thrilled to share that Marinna Madrid, PhD, our Co-Founder & Chief Product Officer, will join global decision makers in life sciences at the Longwood Healthcare Leaders Boston CEO Forum on Monday, October 28, 2024 in #Boston. Moderator Andrew Obenshain, CEO of bluebird bio, will lead the panel “Biomanufacturing: Planning for Future Success” at 3:40 pm ET, discussing the latest research and development of biomanufacturing technologies. Marinna will speak on Cellino’s scalable automation and manufacturing solution for personalized regenerative medicines, joining panelists Al Gianchetti, CEO of XyloCor Therapeutics, Inc., and Hari Pujar, COO of Tessera Therapeutics. We’re looking forward to another engaging discussion and joining fellow leaders across the #healthcare ecosystem to further advance personalized medicines! 🗓️ Learn more about the meeting here: https://bit.ly/4dT37mf #BostonCEO #Biomanufacturing #Leadership #RegenMed #Innovation #PersonalizedMedicine #FutureofMedicine #Therapeutics #Cellino #YourCellsYourCure